Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression

Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Theranostics
Prif Awduron: Shi, Linlin, Sheng, Jianyong, Wang, Mengli, Luo, Han, Zhu, Jun, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ivyspring International Publisher 2019
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592171/
https://ncbi.nlm.nih.gov/pubmed/31281535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35131
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg